Gault J, Nussbaum A
Open Access J Transl Med Res. 2021; 2(3):84-91.
PMID: 34079927
PMC: 8168627.
DOI: 10.15406/oajtmr.2018.02.00043.
Calarge C, Ivins S, Motyl K, Shibli-Rahhal A, Bliziotes M, Schlechte J
Ther Adv Psychopharmacol. 2013; 3(5):278-93.
PMID: 24167704
PMC: 3805387.
DOI: 10.1177/2045125313487548.
Molitch M
Pituitary. 2008; 11(2):209-18.
PMID: 18404390
DOI: 10.1007/s11102-008-0106-6.
de Visser S, van der Post J, Pieters M, Cohen A, van Gerven J
Br J Clin Pharmacol. 2001; 51(2):119-32.
PMID: 11259983
PMC: 2014436.
DOI: 10.1111/j.1365-2125.2001.01308.x.
Jullien Y, Desch G, Bonardet A, Alloua D, deRodez M, Descomps B
Can Anaesth Soc J. 1982; 29(5):468-72.
PMID: 7127180
DOI: 10.1007/BF03009410.
Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate.
Jorgensen A, Andersen J, Bjorndal N, Dencker S, Lundin L, Malm U
Psychopharmacology (Berl). 1982; 77(1):58-65.
PMID: 6812119
DOI: 10.1007/BF00436100.
Prolactin response to exercise, metoclopramide and other provacative agents in children.
Ijaiya K
Eur J Pediatr. 1980; 134(3):231-7.
PMID: 6775949
DOI: 10.1007/BF00441478.
Haloperidol plasma levels and clinical response in paranoid schizophrenics.
Linkowski P, Hubain P, von Frenckell R, Mendlewicz J
Eur Arch Psychiatry Neurol Sci. 1984; 234(4):231-6.
PMID: 6526061
DOI: 10.1007/BF00381354.
Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.
Muller E, Locatelli V, Cella S, Penalva A, Novelli A, Cocchi D
Drugs. 1983; 25(4):399-432.
PMID: 6133737
DOI: 10.2165/00003495-198325040-00004.
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Angrist B, Rotrosen J, Gershon S
Psychopharmacology (Berl). 1980; 67(1):31-8.
PMID: 6102776
DOI: 10.1007/BF00427592.
Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Angrist B, Peselow E, Rubinstein M, WOLKIN A, Rotrosen J
Psychopharmacology (Berl). 1985; 85(3):277-83.
PMID: 2860683
DOI: 10.1007/BF00428187.
Lithium increases 5-HT-mediated prolactin release.
McCance S, Cohen P, Cowen P
Psychopharmacology (Berl). 1989; 99(2):276-81.
PMID: 2508166
DOI: 10.1007/BF00442822.
Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication.
Lal S, Nair N, Thavundayil J, Tawar V, Quirion R, Guyda H
J Neural Transm Gen Sect. 1991; 85(2):157-64.
PMID: 1930878
DOI: 10.1007/BF01244707.
Clinical pharmacology of prochlorperazine in healthy young males.
Isah A, Rawlins M, Bateman D
Br J Clin Pharmacol. 1991; 32(6):677-84.
PMID: 1768559
PMC: 1368546.
Does metergoline selectively attenuate 5-HT mediated prolactin release?.
Ellis P, Gartside S, Ware C, Campling G, Cowen P
Psychopharmacology (Berl). 1991; 105(1):129-31.
PMID: 1745704
DOI: 10.1007/BF02316875.
Prolactin releasing effect of sulpiride isomers in rats and man.
Muller E, Stefanini E, Camanni F, Locatelli V, MASSARA F, Spano P
J Neural Transm. 1979; 46(3):205-14.
PMID: 528995
DOI: 10.1007/BF01250786.
Behavioral and neuroendocrine effects of low dose ET-495: antagonism by haloperidol.
Angrist B, Ain M, Rotrosen J, Gershon S, Halpern F, SACHAR E
J Neural Transm. 1979; 44(4):249-62.
PMID: 458429
DOI: 10.1007/BF01250321.
Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man.
Langer G, SACHAR E, Nathan R, Tabrizi M, Perel J, Halpern F
Psychopharmacology (Berl). 1979; 65(2):161-4.
PMID: 117485
DOI: 10.1007/BF00433043.
Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men.
Rubin R, Hays S
Psychopharmacology (Berl). 1979; 61(1):17-24.
PMID: 108715
DOI: 10.1007/BF00426804.
Normal prolactin responses in tardive dyskinesia.
Asnis G, SACHAR E, Langer G, Halpern F, Fink M
Psychopharmacology (Berl). 1979; 66(3):247-50.
PMID: 43550
DOI: 10.1007/BF00428314.
